PlateletBio
Teresa (Teri) Foy is an immunologist with 25 years of experience in the biotechnology and pharmaceutical industry developing novel therapeutics in the areas of inflammation and immuno-oncology. Teri is currently Corporate Vice President and Head of Celgene’s Immuno-Oncology (IO) and Cellular Therapy (CT) Thematic Center of Excellence (TCoE) in Seattle. Celgene’s IO CT TCoE is focused on development and translation of Celgene’s early IO and Cellular Therapy pipeline from discovery through human proof of concept. Teri joined Celgene in 2014 and established Celgene’s Seattle site. Early in her career Teri held scientific leadership positions at Corixa Corp. and Glaxo Smith Kline, both in Seattle WA. Teri served as the Chief Scientific Officer at VLST, developing therapeutics for autoimmune and inflammatory diseases. She holds a Ph.D. in Immunology from the University of Iowa and completed a post-doctoral fellowship in Immunology at Dartmouth Medical School. Teri has an extensive publication record and holds close to a dozen patents for novel immune compositions.
This person is not in the org chart
This person is not in any offices
PlateletBio
PlateletBio is the only allogeneic cell therapy company focused on platelet biology. The company's approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, they're developing a superior cell therapy empowered to tackle previously unmet medical challenges.